Feedback
Settings

Settings

Goto Application

28,612 results
Offices all Languages Stemming true Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N7/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 2,862
1.WO/2025/144717COMPOSITIONS AND METHODS FOR INDUCING IMMUNE RESPONSE AGAINST EPSTEIN-BARR VIRUSES
WO - 03.07.2025
Int.Class A61K 39/245
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
245Herpetoviridae, e.g. herpes simplex virus
 Appl.No PCT/US2024/061315 Applicant REPLICATE BIOSCIENCE, INC. Inventor ALIAHMAD, Parinaz
The present disclosure relates to nucleic acids molecules, e.g., self-replicating RNA (srRNA) expressing antigenic determinant(s) derived from Epstein-Barr virus (EBV), recombinant cells and pharmaceutical compositions containing the same, as well as the use of such srRNA molecules, recombinant cells, and compositions for eliciting a pharmacodynamic effect in a subject. Also provided are methods for preventing and/or treating various health conditions associated with EBV infection.
2.WO/2025/137783BIOPRODUCT BASED ON LYTIC BACTERIOPHAGE FOR THE CONTROL OF XANTHOMONAS CAMPESTRIS PV. CAMPESTRIS IN BRASSICAS
WO - 03.07.2025
Int.Class A01N 63/00
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF ; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES ; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
63Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
 Appl.No PCT/CL2023/050144 Applicant PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE Inventor ROSALES, Marlen
The invention relates to the use of a lytic bacteriophage, stabilised in a carrier, of the family Myoviridae, Foxunavirus genus (deposit IDAC 261122-01), which acts as a biocontroller of Xanthomonas campestris pv. Campestris (Xcc), a phytopathogen responsible for the main disease affecting brassicas globally, angular leaf spot or black rot. In addition, the invention relates to the preparation of a bioproduct comprising the phage and an agronomically acceptable carrier, such as alginate and/or chitosan.
3.WO/2025/143108PSEUDOMONAS AERUGINOSA BACTERIOPHAGE
WO - 03.07.2025
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
 Appl.No PCT/JP2024/046129 Applicant ARROWSMITH INC. Inventor MATSUKAWA, Koji
The present invention provides a bacteriophage having bacteriolytic activity against Pseudomonas aeruginosa, the bacteriophage genome comprising a nucleic acid sequence represented in the genome of a bacteriophage identified by accession numbers NITE BP-04040, NITE BP-04031, NITE BP-04033, NITE BP-04036, NITE BP-04034, NITE BP-04035, accession number NITE ABP-04200, or accession number NITE ABP-04201. The present invention also provides a bacteriophage having bacteriolytic activity against Pseudomonas aeruginosa, the bacteriophage including a nucleic acid sequence encoding a tail fiber gene including at least a portion of a tail fiber gene derived from another bacteriophage and/or a nucleic acid sequence encoding at least one protein or active domain selected from the group consisting of (a) Pyocin G, (b) PslGh, and (c) PelAh.
4.WO/2025/138665NATURAL ATTENUATED STRAIN OF INFECTIOUS LARYNGOTRACHEITIS VIRUS WITH GOOD SAFETY AND GOOD IMMUNOGENICITY AND USE
WO - 03.07.2025
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
 Appl.No PCT/CN2024/102158 Applicant INSTITUTE OF ANIMAL HUSBANDRY AND VETERINARY MEDICINE, FUJIAN ACADEMY OF AGRICULTURAL SCIENCES Inventor HOU, Bo
A natural attenuated strain of infectious laryngotracheitis virus with good safety and good immunogenicity. The natural attenuated strain is named infectious laryngotracheitis virus ILTV FJ19, and has been deposited in the China Center for Type Culture Collection on November 29, 2023, with the deposit number of CCTCC NO: V2023109, and the deposit address of No. 299, Bayi Road, Wuchang District, Wuhan City, Hubei Province. Experiments show that the avian infectious laryngotracheitis virus ILTV FJ19 strain has stable passage ability, can adapt to inoculation via the allantoic cavity route, has very good safety and immunogenicity when inoculated in 14-day-old SPF chickens, can be used for eye-drop inoculation or oral inoculation, and can be used as a candidate strain of a live attenuated vaccine against ILTV.
5.WO/2025/130867METHOD FOR INHIBITING TRANSCRIPTIONAL ACTIVITY OF RESIDUAL AAV VECTOR PLASMID AND PLASMID BACKBONE
WO - 26.06.2025
Int.Class C12N 15/861
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
861Adenoviral vectors
 Appl.No PCT/CN2024/139956 Applicant SUZHOU GENASSIST THERAPEUTICS CO., LTD Inventor HE, Chunyan
Provided are a method for inhibiting the transcriptional activity of a residual AAV vector plasmid and a plasmid backbone, and a nucleic acid construct comprising a transcription-inhibitory element, a recombinant AAV vector plasmid comprising the nucleic acid construct, and an AAV product prepared by using the recombinant AAV vector plasmid. By means of inhibiting the transcriptional activity of ITR in the AAV vector plasmid, the transcription-inhibitory element is used for inhibiting transcription products generated by the residual AAV vector plasmid and the reverse packaging of the plasmid backbone.
6.WO/2025/133247METHODS FOR AAV VECTOR RE-ADMINISTRATION
WO - 26.06.2025
Int.Class C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
 Appl.No PCT/EP2024/088101 Applicant GENETHON Inventor BUJ-BELLO, Ana
The invention relates to a combination of a recombinant AAVpo1 vector and a recombinant AAV9, AAVrh10 or AAVrh74 vector for use in the gene therapy of muscle and/or nervous system disorders in an individual in need thereof.
7.WO/2025/129693RECOMBINANT ONCOLYTIC HERPES VIRUS HAVING AN OXYGEN DEPENDENT DEGRADATION DOMAIN
WO - 26.06.2025
Int.Class C12N 7/01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
01Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
 Appl.No PCT/CN2023/141255 Applicant VIROGIN BIOTECH (SHANGHAI) LTD. Inventor ZHANG, Kuan
Provided herein is a recombinant herpes simplex viruses (HSV) having a modified oncolytic herpes virus genome, wherein the modified oncolytic herpes virus genome comprises an O2-dependent degradation domain (ODD) operably linked to a copy of an HSV gene.
8.WO/2025/132695RECOMBINANT RHABDOVIRUS ENCODING FOR A GASDERMIN
WO - 26.06.2025
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
 Appl.No PCT/EP2024/087270 Applicant BOEHRINGER INGELHEIM INTERNATIONAL GMBH Inventor NOLDEN, Tobias
The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a gasdermin. The invention is further directed to the use of the recombinant virus in the treatment of cancer and also to methods for producing such viruses.
9.20250207106COMPOSITION AND METHODS FOR ADENO-ASSOCIATED VIRUS PRODUCING STABLE HUMAN EMBRYONIC KIDNEY-293 CELL LINES
US - 26.06.2025
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
 Appl.No 18990358 Applicant GENENTECH, INC. Inventor Chi Kin Domingos Ng

The presently disclosed subject matter relates to compositions and methods for the generation of stable human embryonic kidney-293 (HEK-293) cell lines for adeno-associated virus (AAV) production.

10.WO/2025/129231A DIRECTED EVOLUTION SYSTEM
WO - 26.06.2025
Int.Class C12N 15/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
10Processes for the isolation, preparation or purification of DNA or RNA
 Appl.No PCT/AU2024/050763 Applicant THE UNIVERSITY OF SYDNEY Inventor HESSELSON, Daniel
The present invention relates to a system for evolving a target biomolecule, methods of using such system and composition comprising said system.
# -